Vigil Neuroscience Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Die Erträge von Vigil Neuroscience sind jährlich um durchschnittlich -16.4% zurückgegangen, während in der Branche Biotechs die Erträge jährlich um gewachsen sind und sich dabei auf 19.3% belaufen.

Wichtige Informationen

-16.4%

Wachstumsrate der Gewinne

114.3%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	n/a
Eigenkapitalrendite	-93.3%
Netto-Marge	n/a
Letzte Ertragsaktualisierung	30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Keine Aktualisierungen

Recent updates

We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully

Oct 17

We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate

May 30

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Feb 01

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Oct 14

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Jun 27

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Mar 14

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Nov 29

Aufschlüsselung der Einnahmen und Ausgaben

Wie Vigil Neuroscience Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:VIGL Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Sep 24	-83	28	60
30 Jun 24	-84	28	62
31 Mar 24	-83	28	61
31 Dec 23	-83	28	61
30 Sep 23	-79	28	56
30 Jun 23	-76	25	54
31 Mar 23	-73	23	51
31 Dec 22	-68	21	47
30 Sep 22	-63	19	44
30 Jun 22	-56	17	39
31 Mar 22	-50	14	36
31 Dec 21	-43	10	32

Qualität der Erträge: VIGL ist derzeit unrentabel.

Wachsende Gewinnspanne: VIGL ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: VIGL ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 16.4% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von VIGL verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: VIGL ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (16.6%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: VIGL hat eine negative Eigenkapitalrendite (-93.28%), da es derzeit unrentabel ist.

Vigil Neuroscience Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Price target increased by 9.8% to US$17.57

We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully

General Counsel & Corporate Secretary notifies of intention to sell stock

Vigil Neuroscience, Inc. Announces U.S. Food and Drug Administration Removal the Partial Clinical Hold on its Ongoing Phase 1 Clinical Trial of VG-3927

New major risk - Financial position

Vigil Neuroscience, Inc. Announces Interim Data from Its Ongoing Phase 1 Clinical Trial Evaluating Vv-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease

Vigil Neuroscience, Inc. Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell Small Cap Comp Value Index

Vigil Neuroscience, Inc. announced that it expects to receive $39.99997 million in funding from Sanofi Pasteur Biologics, LLC, Aventis Inc.

Vigil Neuroscience, Inc. announced that it has received $3.999997 million in funding from Sanofi Pasteur Biologics, LLC

New major risk - Share price stability

We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate

New major risk - Revenue and earnings growth

Price target increased by 8.4% to US$18.57

New minor risk - Market cap size

Vigil Neuroscience, Inc., Annual General Meeting, Jun 05, 2024

Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting

New minor risk - Shareholder dilution

Price target increased by 10% to US$18.86

New major risk - Revenue and earnings growth

Vigil Neuroscience, Inc. Announces Executive Changes

New minor risk - Market cap size

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

New minor risk - Market cap size

Price target decreased by 14% to US$17.13

Vigil Neuroscience, Inc. Reports Positive Interim Data from Phase 2 Ignite Proof-Of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

New major risk - Revenue and earnings growth

Vigil Neuroscience, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating Vv-3927, a Small Molecule Trem2 Agonist, for Potential Treatment of Alzheimer's Disease

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Vigil Neuroscience, Inc Provides an Update on the Small Molecule TREM2 Agonist, VG-3927

Vigil Neuroscience, Inc. Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for Vgl101 for the Treatment of ALSP

Vigil Neuroscience, Inc. Presents VGL101 Complete Phase 1 Data and Phase 2 Ignite Trial Design at the 2023 American Neurological Association Annual Meeting

New major risk - Share price stability

Vigil Neuroscience, Inc. Appoints Christopher J. Silber, M.D. as Chief Medical Officer

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Vigil Neuroscience, Inc. Appoints Samantha Budd Haeberlein to Its Board of Directors

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Vigil Neuroscience, Inc. Announces Resignation of Shaan Gandhi, from Member of Board of Directors

High number of new and inexperienced directors

Vigil Neuroscience, Inc. Announces Executive Changes

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Chief Medical Officer notifies of intention to sell stock

Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP

Vigil draws bullish view at Wedbush on upcoming readout for lead asset

Vigil Neuroscience, Inc. announced that it has received $74.999705 million in funding from Deep Track Capital, LP, BVF Partners L.P., Deerfield Management Company, L.P. Series C, Dafna Capital Management, LLC, The Invus Group, LLC

Vigil Neuroscience, Inc. announced that it expects to receive $74.999705 million in funding from Deep Track Capital, LP, BVF Partners L.P., Deerfield Management Company, L.P. Series C, Dafna Capital Management, LLC, The Invus Group, LLC

Vigil Neuroscience announces $75M PIPE financing

Vigil Neuroscience Appoints Suzanne Bruhn to Its Board of Directors

We're Hopeful That Vigil Neuroscience (NASDAQ:VIGL) Will Use Its Cash Wisely

Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 2000 Growth Index

Vigil Neuroscience, Inc. Expands VGL101 Phase 1 Trial to Australia

Vigil Neuroscience, Inc. Appoints Christopher Verni as General Counsel and Mary Thistle to Its Board of Directors

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Invest In Growth?

Vigil Neuroscience, Inc. has completed an IPO in the amount of $98 million.

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren